间充质干细胞移植治疗肝细胞衰竭：一个新方向与选择
Mesenchymal Stem Cell Transplantation for Liver Cell Failure: A New Direction and Option.
作者信息
Cao Yantian, Zhang Bangjie, Lin Rong, Wang Qingzhi, Wang Jie, Shen Fangfang
机构信息
Department of Gastroenterology, The Third Affiliated Hospital, Xinxiang Medical University, Hua Lan Avenue, Xinxiang, Henan Province 453003, China.
Department of Gastroenterology, Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Avenue, Wuhan, Hubei Province 430022, China.
出版信息
Gastroenterol Res Pract. 2018 Mar 4;2018:9231710. doi: 10.1155/2018/9231710. eCollection 2018.
BACKGROUND AND AIMS
Mesenchymal stem cell transplantation (MSCT) became available with liver failure (LF), while the advantages of MSCs remain controversial. We aimed to assess clinical advantages of MSCT in patients with LF.
METHODS
Clinical researches reporting MSCT in LF patients were searched and included.
RESULTS
Nine articles ( = 476) related with LF patients were enrolled. After MSCT, alanine aminotransferase (ALT) baseline decreased largely at half a month ( < 0.05); total bilirubin (TBIL) baseline declined to a certain stable level of 78.57 mol/L at 2 and 3 months ( < 0.05). Notably, the decreased value ( value) of Model for End-Stage Liver Disease score (MELD) of acute-on-chronic liver failure (ACLF) group was higher than that of chronic liver failure (CLF) group (14.93 ± 1.24 versus 4.6 ± 5.66, < 0.05). Moreover, MELD baseline of ≥20 group was a higher D value of MELD than MELD baseline of <20 group with a significant statistical difference after MSCT ( = 0.003).
CONCLUSION
The early assessment of the efficacy of MSCT could be based on variations of ALT at half a month and TBIL at 2 and 3 months. And it had beneficial effects for patients with LF, especially in ACLF based on the value of MELD.
背景与目的
间充质干细胞移植（MSCT）已应用于肝衰竭（LF）患者，而间充质干细胞的优势仍存在争议。我们旨在评估MSCT在LF患者中的临床优势。
方法
检索并纳入报道MSCT治疗LF患者的临床研究。
结果
纳入9篇与LF患者相关的文章（n = 476）。MSCT后，半个月时丙氨酸转氨酶（ALT）基线大幅下降（P < 0.05）；总胆红素（TBIL）基线在2个月和3个月时降至78.57 μmol/L的一定稳定水平（P < 0.05）。值得注意的是，慢加急性肝衰竭（ACLF）组终末期肝病模型评分（MELD）的下降值（Δ值）高于慢性肝衰竭（CLF）组（14.93 ± 1.24对4.6 ± 5.66，P < 0.05）。此外，MSCT后，MELD基线≥20组的MELD Δ值高于MELD基线<20组，差异有统计学意义（P = 0.003）。
结论
MSCT疗效的早期评估可基于半个月时ALT及2个月和3个月时TBIL的变化。并且MSCT对LF患者有有益作用，尤其是基于MELD的Δ值对ACLF患者。
Zotero 插件